Navigation Links
Stereotaxis and Siemens Promote Integrated Odyssey(TM) Solutions
Date:5/12/2010

ST. LOUIS, May 12 /PRNewswire-FirstCall/ -- At the Heart Rhythm Society's 31st Annual Scientific Sessions, Stereotaxis, Inc. (Nasdaq: STXS) will promote its Odyssey Enterprise Solution with a live network connection between the Stereotaxis and Siemens Healthcare exhibits.  The demonstration will be remotely powered through the Stereotaxis Odyssey Enterprise Cinema platform connected to a customer viewing station in the Siemens booth to demonstrate the capability of remote viewing, recording and collaboration in Siemens large display for Artis zee® labs.  Attendees will experience the innovative features of Odyssey Enterprise Cinema and Network Connect in combination with the Siemens consolidated display.  The exhibits will be open from May 13 to 15 at the Colorado Convention Center in Denver, Colorado, with each company offering its components for sale at HRS.

"Siemens remains focused on delivering innovative solutions to our cardiology customers, such as the ability to acquire three-dimensional images of the heart's structures utilizing syngo® DynaCT Cardiac and to distribute and display the information to the clinical team to support decision-making," said Claus Grill, vice president, Cardiac, Interventional/Neuro, and X-ray Systems, Siemens Healthcare. "Odyssey Enterprise Cinema and Network Connect is clearly aligned with this initiative by delivering synchronized data from Siemens labs throughout hospital networks and around the world."

"The integration of state-of-the-art Siemens labs with Odyssey Enterprise Solutions provides a great opportunity for Stereotaxis," said Michael P. Kaminski, Stereotaxis President and CEO. "The combination of the large display solution from Siemens with Odyssey offers a powerful combination of products that will deliver real value to our joint customers."  

About Odyssey   www.OdysseyExperience.com

The Odyssey portfolio of products provides an innovative enterprise solution for integrating, recording, and networking interventional lab information around the world.  Odyssey Vision standardizes data integration for magnetic and standard interventional labs by enhancing the physician workflow through a consolidated display of multiple systems and eliminating the challenge of interacting simultaneously with many separate diagnostic systems.  Odyssey Enterprise Cinema then captures a complete record of synchronized procedure data that can be viewed live or from a comprehensive archive of cases performed.  Through its proprietary data compression technology, Cinema enables sharing of live and recorded procedure data via a laptop anywhere over a secure high speed Internet connection.  Hospitals can also share procedures with other institutions using Odyssey Network Connect providing a global forum for defining clinical best practices across a broad spectrum of medical procedures.

About Stereotaxis   www.Stereotaxis.com

Stereotaxis designs, manufactures and markets an advanced cardiology instrument control system for use in a hospital's interventional surgical suite to enhance the treatment of coronary artery disease and arrhythmias. The Stereotaxis System is designed to enable physicians to complete more complex interventional procedures by providing image guided delivery of catheters and guidewires through the blood vessels and chambers of the heart to treatment sites. This is achieved using computer-controlled, externally applied magnetic fields that govern the motion of the working tip of the catheter or guidewire, resulting in improved navigation, shorter procedure time and reduced x-ray exposure. Stereotaxis' Odyssey solutions integrate and manage information from disparate information sources, eliminating the challenge of interacting simultaneously with many separate diagnostic systems, driving optimized workflow and improved productivity. The core components of the Stereotaxis system have received regulatory clearance in the U.S., Europe and Canada.

This press release includes statements that may constitute "forward-looking" statements, usually containing the words "believe," "estimate," "project," "expect" or similar expressions.  Forward-looking statements inherently involve risks and uncertainties that could cause actual results to differ materially from the forward-looking statements.  Factors that would cause or contribute to such differences include, but are not limited to, continued acceptance for the Company's products in the marketplace, the effect of global credit and economic conditions on the ability and willingness of customers to purchase our systems, competitive factors, changes in government reimbursement procedures, dependence upon third-party vendors, timing of regulatory approval and return of the irrigated catheter to the market, and other risks discussed in the Company's periodic and other filings with the Securities and Exchange Commission.  By making these forward-looking statements, the Company undertakes no obligation to update these statements for revisions or changes after the date of this release.  There can be no assurance that the Company will recognize revenue related to its purchase orders and other commitments in any particular period or at all because some of these purchase orders and other commitments are subject to contingencies that are outside of the Company's control.  In addition, these orders and commitments may be revised, modified or canceled, either by their express terms, as a result of negotiations, or by project changes or delays.


'/>"/>
SOURCE Stereotaxis, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Stereotaxis Announces Vdrive(TM), a New Technology for Remote Navigation of Diagnostic Devices
2. Stereotaxis Updates Progress on Major Clinical Initiative Related to Electrophysiology (EP) Treatment of Ventricular Tachycardia
3. Stereotaxis Installs First System in Taiwan
4. Stereotaxis System Procedure Featured on NBCs The TODAY Show
5. Stereotaxis is Notified of the FDA Approval of an Additional Magnetic Irrigated Catheter
6. Stereotaxis Receives Notice of European Approval of an Additional Magnetic Irrigated Catheter
7. Stereotaxis Announces Underwriters Exercise of Over-Allotment Option
8. Stereotaxis Announces Pricing of $26 Million Common Stock Offering
9. Stereotaxis Announces Public Offering of Common Stock
10. Stereotaxis Receives Commitment to Increase and Extend Its Credit Facility With Silicon Valley Bank
11. Stereotaxis Market Leadership Reinforced in Core Curriculum and Symposium Presentations at Heart Rhythm 2008
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... SAN CLEMENTE, Calif. , June 24, 2016 /PRNewswire/ ... pulmonary function testing company, is now able to perform sophisticated lung ... ndd Medical Technologies , Inc. Patients are ... labs.  Thanks to ndd,s EasyOne PRO ® , ARL patients like ... any needed testing done in the comfort of her own home. ...
(Date:6/24/2016)...  Arkis BioSciences, a leading innovator in the ... cerebrospinal fluid treatments, today announced it has secured ... led by Innova Memphis, followed by Angel Capital ... Arkis, new financing will accelerate the commercialization of ... of its in-licensed Endexo® technology. ...
(Date:6/23/2016)... startling report released today, National Safety Council research shows ... plan to eliminate prescription opioid overdoses. Prescription Nation ... the worst drug crisis in recorded U.S. history, assigned a "Making ... , New Mexico , Tennessee ... states, three – Michigan , Missouri ...
Breaking Medicine Technology:
(Date:6/25/2016)... ... June 25, 2016 , ... "With 30 hand-drawn hand gesture ... said Christina Austin - CEO of Pixel Film Studios. , ProHand Cartoon’s package ... Final Cut Pro X . Simply select a ProHand generator and drag it ...
(Date:6/25/2016)... ... 25, 2016 , ... Conventional wisdom preaches the benefits of moderation, whether it’s ... setting the bar too high can result in disappointment, perhaps even self-loathing. However, those ... goal. , Research from PsychTests.com reveals that behind the tendency to ...
(Date:6/24/2016)... ... 24, 2016 , ... The Pulmonary Hypertension Association (PHA) learned ... receive two significant new grants to support its work to advance research and ... by recognizing patients, medical professionals and scientists for their work in fighting pulmonary ...
(Date:6/24/2016)... ... ... People across the U.S. are sharpening their pencils and honing their writing ... which patients and their families pay tribute to a genetic counselor by nominating him ... Genetic Counselors (NSGC) Annual Education Conference (AEC) this September. , In April, Genome ...
(Date:6/24/2016)... ... ... recruitment firm Slone Partners is pleased to announce the placement of Suzanne ... of North American Capital Sales at HTG Molecular . , In ... commercialization of the HTG EdgeSeq system and associated reagents in North America. , Headquartered ...
Breaking Medicine News(10 mins):